Status:
COMPLETED
A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Conditions:
HCV Infection
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this follow-up study is to evaluate the frequency and persistence of specific viral mutations in response to treatment with ABT-333 (dasabuvir).
Detailed Description
This Phase 2, multicenter study was conducted in HCV-infected participants who received ABT-333 at any dose level or matching placebo in a prior clinical study involving ABT-333. Hepatitis C virus (HC...
Eligibility Criteria
Inclusion
- \- Main Selection Criteria: Subject received ABT-333 or matching placebo in a prior clinical study involving ABT-333.
Exclusion
- \- The investigator considers the subject unsuitable for the study for any reasons inclusive of, but not limited to, failure to comply with study procedures in prior ABT-333 clinical study.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00726882
Start Date
August 1 2008
End Date
May 1 2010
Last Update
January 8 2015
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 17665
Anaheim, California, United States, 92801
2
Site Reference ID/Investigator# 17367
Los Angeles, California, United States, 90036
3
Site Reference ID/Investigator# 17672
Los Angeles, California, United States, 90048
4
Site Reference ID/Investigator# 10381
Orlando, Florida, United States, 32803